drugset / Trial / NCT05936281
A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
Phase 2
Completed
165 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Huashan Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of Genakumab in prevention of acute flares in gout patients initiating urate-lowering therapyurate-lowering
Timeline
- Start
- 2023-07-20
- Primary completion
- 2024-01-19
- Completion
- 2024-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Colchicine | Small molecule | 0.5 mg | Oral |
| Subject | Genakumab | Monoclonal antibody | 100 mg | Other |
| Subject | Genakumab | Monoclonal antibody | 200 mg | Other |